Payment overview · 2025
General Payments
$361.44
4 reported records · 3 companies
Healthcare provider profile · identity verified
Anamaris Ibarra
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SOUTH MIAMI, FL · NPI 1013469766
Verified facts
What the public records show
CMS Open Payments records show Anamaris Ibarra received $361.44 in general payments during 2025 across 4 reported records.
Medtronic, Inc. accounted for 78.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Afrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$281.92 | 78.0% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 11.8% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $37.02 | 10.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $281.92 | 1 |
| Education | $42.50 | 1 |
| Food and Beverage | $37.02 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $281.92 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $37.02 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 557 | 195 |
| Ozempic | Semaglutide | 552 | 124 |
| Mounjaro | Tirzepatide | 483 | 101 |
| Synthroid | Levothyroxine Sodium | 208 | 79 |
| Glimepiride | Glimepiride | 187 | 68 |
| Trulicity | Dulaglutide | 161 | 35 |
| Metformin Hcl | Metformin Hcl | 147 | 63 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 139 | 59 |
| Vascepa | Icosapent Ethyl | 130 | 33 |
| Tradjenta | Linagliptin | 102 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 100 | 28 |
| Farxiga | Dapagliflozin Propanediol | 95 | 23 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 38 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 86 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 28 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 81 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 80 | 21 |
| Humalog Kwikpen U-200 | Insulin Lispro | 79 | 24 |
| Rybelsus | Semaglutide | 78 | 26 |
| Prolia | Denosumab | 77 | 55 |
| Jardiance | Empagliflozin | 74 | 26 |
| Synjardy | Empagliflozin/Metformin Hcl | 73 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 29 |
| Kerendia | Finerenone | 40 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 40 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 37 | 12 |
| Novolog Flexpen | Insulin Aspart | 37 | 14 |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | 13 |
| Gabapentin | Gabapentin | 31 | 11 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 31 | suppressed |
| Mupirocin | Mupirocin | 30 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 28 | 12 |
| Simvastatin | Simvastatin | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Losartan Potassium | Losartan Potassium | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Dexamethasone | Dexamethasone | 19 | 16 |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | 18 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 14 | suppressed |
| Cabergoline | Cabergoline | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 14 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 14 | suppressed |
| Afrezza | Insulin Regular, Human | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Cytomel | Liothyronine Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.44 · 4 records | Medtronic, Inc. | AFREZZA, MINIMED 780G, TWIIST | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Mannkind Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error